A Study Assessing Incidence and Incidence Rate Ratios (IRRs) of Hospital Admissions Among Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Newly Treated With Enzalutamide (ENZA) or Abiraterone (ABI)

Trial Profile

A Study Assessing Incidence and Incidence Rate Ratios (IRRs) of Hospital Admissions Among Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Newly Treated With Enzalutamide (ENZA) or Abiraterone (ABI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2017

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jul 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top